Implementation of a new method to track propofol in an endoscopy unit

Research output: Contribution to journalArticle

Abstract

Aim: Propofol is a widely used anesthesia induction agent and is easily accessible in most healthcare facilities. Unlike regulated or schedule drugs, propofol is inconsistently tracked, leading to inaccurate inventories, incorrect billing, and unrecognized diversion. The goal of this project was to implement a new method of tracking propofol in a single setting, with the aim of accounting for 100% of the drug. Methods: For two, 2-week observation periods, data were extracted from an automated medication management system or pharmacy inventory system, anesthesia records, and pharmacy billing sheets for cases in a Gastrointestinal (GI) Endoscopy Unit, and compared pre-implementation and post-implementation of a new tracking and accounting protocol. Variables included amount of propofol inventoried, dispensed, administered, returned, billed, wasted, and missing. Results: Pre-implementation (n=300), 10% cases had no record of propofol removal from the automated medication system. Of the 90% that did, 25% had an amount signed out that did not match the amount administered. Thirty-one percent of all propofol was unaccounted for during this 2-week period. Furthermore, 19.7% of cases did not have a billing form located. Post-implementation of the process change, unaccounted for propofol decreased to 26% of all cases (P=ns). The percentage of missing billing forms decreased from 19.7 to 5.8% (P=0.00). Conclusion: Data suggest notable amounts of propofol were unaccounted for and not billed for in the GI Endoscopy Unit prior to the protocol change. Post-protocol change data reveal modest improved accounting of the medication and significant cost-capture. Improvements may enhance inventory reconciliation, availability of drug stock, and potentially result in a decreased risk of unrecognized diversion.

Original languageEnglish (US)
Pages (from-to)102-110
Number of pages9
JournalInternational Journal of Evidence-Based Healthcare
Volume15
Issue number3
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Propofol
Endoscopy
Medication Systems
Gastrointestinal Endoscopy
Equipment and Supplies
Anesthesia
Pharmaceutical Preparations
Appointments and Schedules
Observation
Delivery of Health Care
Costs and Cost Analysis

Keywords

  • Anesthetist
  • Diversion prevention
  • Drug abuse
  • Drug security
  • Propofol

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Implementation of a new method to track propofol in an endoscopy unit. / Horvath, Catherine.

In: International Journal of Evidence-Based Healthcare, Vol. 15, No. 3, 01.09.2017, p. 102-110.

Research output: Contribution to journalArticle

@article{b67688c396884ae88f94ba39591952a4,
title = "Implementation of a new method to track propofol in an endoscopy unit",
abstract = "Aim: Propofol is a widely used anesthesia induction agent and is easily accessible in most healthcare facilities. Unlike regulated or schedule drugs, propofol is inconsistently tracked, leading to inaccurate inventories, incorrect billing, and unrecognized diversion. The goal of this project was to implement a new method of tracking propofol in a single setting, with the aim of accounting for 100{\%} of the drug. Methods: For two, 2-week observation periods, data were extracted from an automated medication management system or pharmacy inventory system, anesthesia records, and pharmacy billing sheets for cases in a Gastrointestinal (GI) Endoscopy Unit, and compared pre-implementation and post-implementation of a new tracking and accounting protocol. Variables included amount of propofol inventoried, dispensed, administered, returned, billed, wasted, and missing. Results: Pre-implementation (n=300), 10{\%} cases had no record of propofol removal from the automated medication system. Of the 90{\%} that did, 25{\%} had an amount signed out that did not match the amount administered. Thirty-one percent of all propofol was unaccounted for during this 2-week period. Furthermore, 19.7{\%} of cases did not have a billing form located. Post-implementation of the process change, unaccounted for propofol decreased to 26{\%} of all cases (P=ns). The percentage of missing billing forms decreased from 19.7 to 5.8{\%} (P=0.00). Conclusion: Data suggest notable amounts of propofol were unaccounted for and not billed for in the GI Endoscopy Unit prior to the protocol change. Post-protocol change data reveal modest improved accounting of the medication and significant cost-capture. Improvements may enhance inventory reconciliation, availability of drug stock, and potentially result in a decreased risk of unrecognized diversion.",
keywords = "Anesthetist, Diversion prevention, Drug abuse, Drug security, Propofol",
author = "Catherine Horvath",
year = "2017",
month = "9",
day = "1",
doi = "10.1097/XEB.0000000000000112",
language = "English (US)",
volume = "15",
pages = "102--110",
journal = "International Journal of Evidence-Based Healthcare",
issn = "1744-1595",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Implementation of a new method to track propofol in an endoscopy unit

AU - Horvath, Catherine

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Aim: Propofol is a widely used anesthesia induction agent and is easily accessible in most healthcare facilities. Unlike regulated or schedule drugs, propofol is inconsistently tracked, leading to inaccurate inventories, incorrect billing, and unrecognized diversion. The goal of this project was to implement a new method of tracking propofol in a single setting, with the aim of accounting for 100% of the drug. Methods: For two, 2-week observation periods, data were extracted from an automated medication management system or pharmacy inventory system, anesthesia records, and pharmacy billing sheets for cases in a Gastrointestinal (GI) Endoscopy Unit, and compared pre-implementation and post-implementation of a new tracking and accounting protocol. Variables included amount of propofol inventoried, dispensed, administered, returned, billed, wasted, and missing. Results: Pre-implementation (n=300), 10% cases had no record of propofol removal from the automated medication system. Of the 90% that did, 25% had an amount signed out that did not match the amount administered. Thirty-one percent of all propofol was unaccounted for during this 2-week period. Furthermore, 19.7% of cases did not have a billing form located. Post-implementation of the process change, unaccounted for propofol decreased to 26% of all cases (P=ns). The percentage of missing billing forms decreased from 19.7 to 5.8% (P=0.00). Conclusion: Data suggest notable amounts of propofol were unaccounted for and not billed for in the GI Endoscopy Unit prior to the protocol change. Post-protocol change data reveal modest improved accounting of the medication and significant cost-capture. Improvements may enhance inventory reconciliation, availability of drug stock, and potentially result in a decreased risk of unrecognized diversion.

AB - Aim: Propofol is a widely used anesthesia induction agent and is easily accessible in most healthcare facilities. Unlike regulated or schedule drugs, propofol is inconsistently tracked, leading to inaccurate inventories, incorrect billing, and unrecognized diversion. The goal of this project was to implement a new method of tracking propofol in a single setting, with the aim of accounting for 100% of the drug. Methods: For two, 2-week observation periods, data were extracted from an automated medication management system or pharmacy inventory system, anesthesia records, and pharmacy billing sheets for cases in a Gastrointestinal (GI) Endoscopy Unit, and compared pre-implementation and post-implementation of a new tracking and accounting protocol. Variables included amount of propofol inventoried, dispensed, administered, returned, billed, wasted, and missing. Results: Pre-implementation (n=300), 10% cases had no record of propofol removal from the automated medication system. Of the 90% that did, 25% had an amount signed out that did not match the amount administered. Thirty-one percent of all propofol was unaccounted for during this 2-week period. Furthermore, 19.7% of cases did not have a billing form located. Post-implementation of the process change, unaccounted for propofol decreased to 26% of all cases (P=ns). The percentage of missing billing forms decreased from 19.7 to 5.8% (P=0.00). Conclusion: Data suggest notable amounts of propofol were unaccounted for and not billed for in the GI Endoscopy Unit prior to the protocol change. Post-protocol change data reveal modest improved accounting of the medication and significant cost-capture. Improvements may enhance inventory reconciliation, availability of drug stock, and potentially result in a decreased risk of unrecognized diversion.

KW - Anesthetist

KW - Diversion prevention

KW - Drug abuse

KW - Drug security

KW - Propofol

UR - http://www.scopus.com/inward/record.url?scp=85028686376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028686376&partnerID=8YFLogxK

U2 - 10.1097/XEB.0000000000000112

DO - 10.1097/XEB.0000000000000112

M3 - Article

C2 - 28509811

AN - SCOPUS:85028686376

VL - 15

SP - 102

EP - 110

JO - International Journal of Evidence-Based Healthcare

JF - International Journal of Evidence-Based Healthcare

SN - 1744-1595

IS - 3

ER -